Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cancer of the Pancreas
- Pancreas Cancer
- Pancreatic Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04536077
- Collaborators
- Celldex Therapeutics
- The Foundation for Barnes-Jewish Hospital
- Investigators
- Principal Investigator: William G Hawkins, M.D. Washington University School of Medicine
Get Well Soon